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Sex is a powerful modulator of disease susceptibility, course and outcome. The gene CACNA1C is
among the best replicated vulnerability genes of bipolar disorder and schizophrenia. The aim of
the present study was to investigate whether sex and a variant in CACNA1C (rs10774035 as a
proxy for the well-acknowledged risk variant rs1006737) inﬂuence psychosocial adaptation in ao.2015.09.012
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400 55562.
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2263A common risk variant in CACNA1Cfunctioning;
Calcium channellarge German patient sample with schizophrenia-spectrum (n=297) and bipolar (n=516)
disorders. We analyzed Global Assessment of Functioning (GAF) scores, retrospectively
collected for different time points during disease course. We investigated whether CACNA1C
sex-dependently modulates longitudinal GAF scores and recovery from episodes of psychiatric
disturbance in the above mentioned disorders. Psychosocial recovery was measured as
difference score between the current GAF score (assessing the last remission) and the worst
GAF score ever during an illness episode. Covariate- adjusted association analyses revealed a
sex  rs10774035 genotype interaction on longitudinal GAF and recovery from illness episodes
only in schizophrenia-spectrum but not in bipolar disorders. In schizophrenia-spectrum affected
males, rs10774035 minor allele (T) carriers had higher GAF scores at three time points
(premorbid, worst ever, current). In contrast, females carrying rs10774035 minor alleles had
impaired recovery from schizophrenia-spectrum episodes. These results encourage further
investigations of gene  sex interactions and longitudinal quantitative phenotypes to unravel
the rich variety of behavioral consequences of genetic individuality.
& 2015 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Acute episodes of schizophrenia-spectrum (SZspec) and bipolar
disorders (BDs) are characterized by a steep decline in overall
psychosocial functioning. Both disorders can have a chronic
course characterized by recurring episodes of intense beha-
vioral symptoms. There is, however, great inter-individual
variation in the severity of impairment over time, ranging from
a single mild episode to chronic impairment without recovery
between episodes. Disease severity can be assessed compre-
hensively by quantifying overall psychosocial functioning on a
single global continuum provided by the Global Assessment of
Functioning (GAF) scale (DSM-IV Axis V). This approach allows
for comparison between disorders and is also more sensitive to
changes over time than symptom-speciﬁc assessments (Endicott
et al., 1976). Changes in psychosocial functioning over time can
be used as a measure of outcome or functional recovery from
episodes of mental disorders (Jobe and Harrow, 2005;
Lieberman et al., 2008).
The sex-speciﬁc genetic architecture of mental disorders
has gained attention lately (Ober et al., 2008), sparked by a
ﬁnding in the Reelin gene that increases the risk to develop
SZspec in females but not males (Shifman et al., 2008).
Subsequent investigation by Goes et al. (2009) also impli-
cated Reelin as a sex-speciﬁc genetic risk factor in BDs,
pointing to a sex-speciﬁc cross-disorder vulnerability locus.
Similarly, evidence for sex-speciﬁc effects of CACNA1C has
recently been established (Strohmaier et al., 2013). CAC-
NA1C, coding for an L-type voltage-gated calcium channel
subunit, is among the most intensively studied genes
involved in the etiology of both BDs and SZspec (Bhat
et al., 2012; Green et al., 2010). Whereas CACNA1C as
susceptibility locus for SZspec and BDs has been identiﬁed
hypothesis-free by case-control genome-wide association
studies (GWAS) its full behavioral consequences have yet
to be elucidated. Therefore, the present study probes the
modulating role of CACNA1C variants on longitudinal out-
come within SZspec and BD patients on a continuous
measure of disease course within cases. We took advantage
of a large German sample (n=813) with measures on the
degree of psychosocial adaptation at different diseasestages. Given that there are well-known sex-speciﬁc differ-
ences in the course of both SZspec (Gur et al., 1996; Leung
and Chue, 2000) and BDs (Azorin et al., 2013; Hendrick
et al., 2000; Kawa et al., 2005; Kessing, 2004), we
hypothesized sex to exert a modulating inﬂuence on the
putative effects of CACNA1C on longitudinal course of global
functioning levels and on recovery from episodes of psy-
chiatric disturbance. Speciﬁcally, we investigated the sex-
dependent association between psychosocial adaptation,
including recovery from illness episodes, and the CACNA1C
single nucleotide polymorphism (SNP) rs10774035. In Eur-
opean populations, this SNP is in strong linkage disequili-
brium (LD) with SNP rs1006737 (r2=1.000 and D0=1.000,
SNAP database http://www.broadinstitute.org/mpg/snap/
), for which genetic associations with SZspec and BDs have
been shown. In line with other studies (e.g. Bigos et al.,
2010), we thus investigated the effects of CACNA1C
rs1006737 via a proxy SNP.2. Experimental procedures
2.1. Participants
813 adult inpatients aged between 17 and 80 years with a
life-time diagnosis of BD (n=516, thereof 443 with bipolar I
disorder, 71 with bipolar II disorder and 2 with bipolar
disorder not otherwise speciﬁed) or SZspec (n=297, thereof
232 with schizophrenia, 49 with schizoaffective disorder,
and 16 with schizophreniform disorder) according to DSM-IV
criteria and a minimum illness duration of 6 months were
included in this study. Diagnoses were established by the
German version of the Structured Clinical Interview for DSM-
IV-TR Axis I Disorders (Diagnostic and Statistical Manual of
Mental Disorders, 4th ed, text revision, SCID-I (First et al.,
2002; Wittchen and Fydrich, 1997). All patients were
recruited from consecutive hospital admissions at the
Central Institute of Mental Health, Mannheim, and the
Department of Psychiatry, University of Bonn, Germany,
for the purpose of psychiatric genetic studies. The study
protocol was approved by the local ethics committees, and
Table 1 Characterization of the SZspec and BD sam-
ples. Data are presented as mean7SD, if not speciﬁed
otherwise. Statistical comparisons between disorder
groups were performed with chi-square (sex), t (duration
of illness and age at onset) or Wilcoxon rank sum test
(premorbid, worst ever and current GAF and recovery).
Overlapping 95% conﬁdence intervals (CI) of MAF esti-
mates indicate no differences at the 5% signiﬁcance
level, neither between diagnostic groups nor
between sexes.
SZspec BDs Statistic
(df)
p
Sample size
(n)
297 516
CACNA1C SNP rs10774035
MAF795%
CI
0.3670.04 0.3470.03
MAF795%
CI
(females)
0.3770.06 0.3370.04
MAF795%
CI
(males)
0.3570.05 0.3470.04
HWE p 1.00 0.77
Sex (%
female)
45.1 55.6 7.91 (1) 0.005
Duration of illness
Females 10.7710.2 16.6711.0 5.26
(419)
o0.001
Males 9.679.2 17.4713.7 6.81
(388.75)
o0.001
Age at onset
Females 27.078.9 28.1711.7 1.11
(332.96)
0.2662
Males 25.778.1 29.4712.2 3.57
(388.44)
o0.001
Premorbid GAF
Females 85.9710.1 90.679.8 24946 o0.001
Males 83.8711.4 91.878.9 27200.5 o0.001
Worst ever GAF
Females 25.879.1 29.179.1 24325 o0.001
Males 25.279.1 29.379.7 23964 o0.001
Current GAF
Females 66.1715.0 78.6714.5 27991 o0.001
Males 60.8715.8 78.3715.3 29535.5 o0.001
Recovery (GAF differential)
Females 40.3715.3 49.5716.6 25535.5 o0.001
Males 35.6714.8 48.9716.1 27492 o0.001
U. Heilbronner et al.2264in accordance with the Declaration of Helsinki. Informed
written consent was obtained prior to study participation
from all participants.
2.2. CACNA1C polymorphism
The C/T (minor allele) polymorphism rs10774035 is in strong
LD with the G/A (minor allele) polymorphism rs1006737 for
European populations (SNAP database; http://www.broad
institute.org/mpg/snap/, r2=1.000, D0=1.000) and was
directly genotyped fulﬁlling standard quality control criteria
(Rietschel et al., 2012). Both SNPs are located in an intron
of the CACNA1C gene. (http://www.ncbi.nlm.nih.gov/pro
jects/SNP/snp_ref.cgi?rs=10774035). Observed minor allele
frequencies (MAFs) for rs10774035 were similar in both
diagnostic groups and sexes, with overlapping 95% conﬁ
dence intervals indicating no differences at the 5% signiﬁ
cance level (see Table 1). In addition to the strong LD with
rs1006737, the genotyped variant rs10774035 is located in a
DNAse I hypersensitive region, according to RegulomeDB
(http://regulomedb.org/snp/chr12/2368673). DNAse I
hypersensitivity indicates a remodeled chromatin state
related to transcriptional activity, as these have lost their
condensed structure and are therefore accessible to regula
tory proteins, e.g. transcription factors.
2.3. Phenotypes
For each subject, we analyzed longitudinal GAF scores
(DSM-IV Axis V), retrospectively collected for different time
points during illness course (see below), as principal depen-
dent variable. Historically, the GAF scale was developed
from the Global Assessment Scale (GAS) which assesses
general psychosocial functioning on a health-illness conti-
nuum ranging from 1 to 100 (Endicott et al., 1976). Brieﬂy,
GAS values of 100–91 correspond to superior psychosocial
functioning, whereas values of 10–1 are used to describe the
low end of this continuum in which an individual needs
constant supervision to avoid damage to itself or others or
to ensure minimal personal hygiene. The GAS was initially
developed by Luborsky (1962) as Health-Sickness Rating
Scale, revised by Endicott et al. (1976) under the name
GAS of which a modiﬁed version was included in the DSM-III-
R (Cooper and Michels, 1988) and, with minimal changes,
also in the DSM-VI as GAF scale (Axis V). GAF information
was assessed for three time points during the individual
disease course:
GAF1: the premorbid GAF, deﬁned as the highest GAF
score present before illness onset
GAF2: the worst GAF score ever, i.e. the lowest GAF
value ever present during an illness episode
GAF3: the current GAF (pre-admission GAF) deﬁned as
the GAF score right before the “current” episode for
which the patient received clinical treatment at the time
of interview
All assessments were performed by board-certiﬁed psychia-
trists or psychologists or psychiatry/psychology trainees at
advanced stages in their postgraduate education. GAF1 and
GAF2 were retrospectively assessed based on a multitude ofsources to increase the validity of this retrospective assess-
ment, including a structured diagnostic interview with the
patient, a thorough examination of clinical records, and family
interview method, whenever possible, The difference score of
GAF3 and GAF2 (“current status” (last remission) minus “worst
ever”) served as a measure for the degree of recovery from
episodes of psychiatric disorder. We analyzed all participants
for whom information on rs10774035 genotype, age, duration
of illness and GAF scores were complete.
Table 2 Sex-dependent CACNA1C effects on longitudi-
nal GAF and recovery from episodes.
SZspec BDs
Sample size (n) 297 516
Global analysis: CACNA1C sex interaction
Longitudinala: GAF1, 2,
3 (p)
0.012 0.870
Sex-stratiﬁed: CACNA1C main effects
Males Females Not
applicable
Sample size (n) 163 134
Longitudinala: GAF1, 2,
3 (p)
0.018 0.482
Recoveryb (p) 0.966 0.042
p-values o0.05 are highlighted in bold.
aLongitudinal rank-sum test LNPT (average rs10774035
effects on GAF over all three time points): joint analysis of
covariate-adjusted linear regression residuals of premorbid,
worst ever, and current GAF scores. Latter were adjusted for
age at illness onset (premorbid GAF) or duration of illness
(worst ever GAF, current GAF), separately for females
and males.
bNon-longitudinal rank-sum test nparcomp on covariate-
adjusted residual recovery in males or females. Residual
recovery is the regression residual obtained on the differ-
ence score between current GAF minus worst ever GAF. This
difference score was adjusted for duration of illness and
premorbid GAF, separately for females and males.
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We used the software R (version 3.0.2, www.r-project.org). All
p-values reported are two-sided. BD and SZspec samples were
analyzed separately as well-known sex-speciﬁc differences in
the course of SZspec and BD may yield different interaction
patterns with sex. GAF values covary with sex and age at illness
onset (premorbid GAF) or with sex and duration of illness
(worst ever and current GAF, see Gade et al. (2015). We
therefore adjusted GAF scores by linear regression for age at
illness onset or duration of illness, separately for females and
males. The GAF linear regression residuals at all three time
points were jointly analyzed by non-parametric longitudinal
rank-sum test LNPT (Malzahn et al., 2010; R package nparLD:
Noguchi et al., 2012). The LNPT statistic resembles a hetero
scedastic, two-way repeated measures ANOVA with two-level
factor sex and three-level factor CACNA1C rs10774035 geno
type. When a signiﬁcant sex  genotype interaction was
found, subsequent analyses tested rs10774035 main effects
separately in males and females. Sex-stratiﬁed analyses also
considered the recovery phenotype (GAF3 minus GAF2). Latter
was adjusted for sex, duration of illness, and premorbid GAF
(as recovery correlates with premorbid levels of psychosocial
adaptation, data not shown). When analyzing recovery in males
and females, we took advantage of a non-parametric maximum
test (Marcus, 1982) that accounts for the unknown genetic
mode of inheritance (Konietschke et al., 2012; R package
nparcomp). Note that LNPT and nparcomp are both robust
against potential variance heterogeneity between genotype
groups or time points and remain valid and powerful also for
non-normally distributed target variables.
3. Results
Table 1 displays descriptive statistics of and statistical compar-
isons between both diagnostic samples. Clinically expected
differences are a lower percentage of females in SZspec
compared to BDs, earlier age of onset of SZspec in males but
not in females compared to BDs, and consistently lower GAF
scores throughout all three time points as well as worse
recovery in SZspec compared to BDs for men and women.
Patients with BDs had a longer duration of illness at the time of
observation compared to the SZspec patients. All other
statistical test results are covariate-adjusted (including adjust-
ment for sex, age at illness onset, duration of illness) and
displayed in Table 2 (as well as in Figures 1 and 2).
3.1. Longitudinal analysis of covariate-adjusted
residual GAF scores
LNPT detected no sex  CACNA1C interaction in the BD
sample (p=0.870). In contrast, sex  CACNA1C interaction
was signiﬁcant in the SZspec sample (p=0.012, see Table 2).
Figure 1 illustrates that the CACNA1C rs10774035 minor
(T) allele had a beneﬁcial main effect on longitudinal
residual GAF scores in SZspec affected males (p=0.018).
In SZspec affected males, the rs10774035 TT genotype was
associated with elevated median residual GAF scores at all
three time points, compared to the CC and CT genotype
groups. In contrast, SZspec affected females displayed an
opposing - but non-signiﬁcant - tendency towards reducedpremorbid and current median residual GAF scores in
female T allele carriers (LNPT on residual GAF1, 3:
p=0.125). However, residual GAF2 scores behaved differ-
ently (LNPT on residual GAF1, 2, 3: p=0.482, i.e. greatly
increased p-value when including residual GAF2).
3.2. CACNA1C rs10774035 effects on covariate-
adjusted residual recovery from illness episodes
As reported above, CACNA1C rs10774035 genotype affected
residual GAF scores in SZspec males consistently at all three
time points. Correspondingly, residuals of the recovery
phenotype were not signiﬁcantly affected by rs10774035
in SZspec males (p=0.966). In contrast, the rs10774035
minor (T) allele signiﬁcantly reduced residuals of the
recovery phenotype in SZ spec females (p=0.042) consis-
tent with a dominant mode of inheritance (see Figure 2).
The associations of CACNA1C rs10774035 with outcome in
SZspec and non-association with outcome in BDs were also
found when additionally adjusting GAF scores for diagnostic
subcategory and when only analyzing the largest diagnostic
subgroups (schizophrenia, bipolar I disorder), respectively
(data not shown).
4. Discussion
We investigated sex-dependent effects of CACNA1C
rs10774035 genotype, a proxy SNP for the widely studied
Figure 1 CACNA1C rs10774035 affects longitudinal course of functioning in SZspec disorders. Boxplots of covariate-adjusted GAF
score data for males (left) and females (right) with SZspec disorders. The data are grouped according to CACNA1C rs10774035
genotype (white: CC, light shade: CT, dark shade: TT) and time point of measurement (premorbid, worst ever, current). Sample sizes
are identical at all three time points (CC/CT/TT: males – n=67/77/19; females – n=54/60/20). p-values of covariate-adjusted
nonparametric longitudinal analyses (LNPT: joint analysis of the three time points) are given.
U. Heilbronner et al.2266CACNA1C risk variant rs1006737, in SZspec and BDs. We used
GAF scores as dependent variables, investigating the course
of psychosocial adaptation with a special emphasis on
recovery from illness episodes. In the following, we discuss
results of the present study in light of the effects of
CACNA1C in case-control and population-based studies.
For reasons of clarity, we refer to the T allele of
rs10774035 (proxy SNP investigated in the present study)
and the A allele of rs1006737 collectively as CACNA1C minor
allele. Across sexes, it is well known that polymorphisms in
the CACNA1C gene confer susceptibility to SZspec and BD
(Cross-Disorder Group of the Psychiatric Genomics Consor-
tium, Genetic Risk Outcome of Psychosis (G. R. O. U. P)
Consortium; Dao et al., 2010; Ferreira et al., 2008; Green
et al., 2010; Hamshere et al., 2013; Liu et al., 2011;
Moskvina et al., 2009; Nyegaard et al., 2010; Sklar et al.,
2011, 2008; Wray et al., 2012). However, the investigation
of sex-speciﬁc genetic effects underlying disease risk has
shown that the genetic basis for many diseases differs in
males and females (Goes et al., 2009; Liu et al., 2012; Ober
et al., 2008; Shifman et al., 2008). Such differential effect
in females and males have been shown for CACNA1C (Dao
et al., 2010; Strohmaier et al., 2013; Witt et al., 2014) and
an association in one sex may drive the association in a
sample in which sexes are pooled. Given CACNA1C's role in
the etiology of both SZspec and BDs, we hypothesized
longitudinal course of these disorders to be differentially
affected between sexes. Our analyses of GAF levels for
three time points in the disease course revealed evidence
for sex-speciﬁc effects only in the SZspec sample. In line
with the view of schizophrenia being a neurodevelopmental
disorder (Murray and Lewis, 1987; Woods, 1998) this may be
indicative of an early interplay between the sex-speciﬁc
regulatory genome (Ober et al., 2008), a polymorphic
CACNA1C gene and pathophysiology in ontogeny. In SZspec
affected males, the CACNA1C minor allele had a main effecton the level of longitudinal GAF regardless of time point
investigated, with the homozygous genotype having a
beneﬁcial effect (see Figure 1). Our ﬁnding may thus be
considered out of line with results in the population-based
study of Strohmaier et al. (2013), where, in males, the
minor allele was associated with lower resilience pheno-
types. In the present study, recovery in SZspec affected
males was not inﬂuenced by CACNA1C genotype. In marked
contrast, CACNA1C rs10774035 genotype inﬂuenced long-
itudinal course, particularly functional recovery from epi-
sodes, in SZspec affected females. Here, the CACNA1C
minor allele was found to have a detrimental effect,
consistent with a dominant model of inheritance. However,
in females, Strohmaier et al. (2013) found the CACNA1C
minor allele to be associated with resilience phenotypes in
the general population and thus again in contrast to the
present study. These conﬂicting results of our study and that
of Strohmaier et al. (2013) may be explained by acknowl-
edging the fact that different phenotypes were investigated
in different study samples and that the mechanisms under-
lying these phenotypes may play a unique role in health and
disease. Alternatively, these results may be an example of
the so-called ﬂip-ﬂop phenomenon (Lin et al., 2007),
pointing to the explanation that the CACNA1C locus is
correlated with a causal variant. The CACNA1C gene codes
for the pore-forming alpha1C subunit of the voltage-
dependent L-type calcium channel (CaV1.2) (Bhat et al.,
2012). Sequence variation in intronic regions of the gene,
such as the polymorphisms investigated herein, are thought
to inﬂuence not functional channel properties but rather
expression levels and RNA splicing. In support of this, Bigos
et al. (2010) have found greater CACNA1C expression in
carriers of the minor allele. Importantly, calcium ions
themselves play a crucial role in regulating gene expression
(e.g. West et al., 2001). An explanation of the seemingly
incongruent role of rs1006737/rs10774035 in psychiatric
Figure 2 CACNA1C rs10774035 affects recovery from SZspec episodes. Upper row: covariate-adjusted residual recovery from
episodes of SZ-spectrum disorders, stratiﬁed by sex and CACNA1C rs10774035 genotype. Lower row: nonparametric test for
dominant, additive and recessive modes of inheritance of the CACNA1C rs10774035 minor (T) allele. Signiﬁcant results do not
include the dotted line at value 0.5.
2267A common risk variant in CACNA1Cdisease may thus stem from the fact that CACNA1C is a
major regulator of downstream processes itself via the
regulation of intracellular calcium concentration.
Besides rs1006737, CACNA1C rs1024582 and rs2007044
have recently been implicated as putative pathogenic loci
by GWAS (Cross-Disorder Group of the Psychiatric Genomics
Consortium, Genetic Risk Outcome of Psychosis (G. R. O. U.
P) Consortium; Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014). Both loci are in
high LD with rs1006737 (rs1024582: r2=0.933, D0=1.000;
rs2007044: r2=0.788, D0=1.000). Data on rs2007044 were
available for our sample and associated similarly but slightly
weaker (data not shown) compared to the rs1006737 proxy
rs10774035.
Overall, our results suggest that molecular genetic stu-
dies using longitudinal and/or sex-speciﬁc analyses of
quantitative traits underlying mental disorders have the
potential to unravel complex genetic interactions. To our
knowledge, this is also the ﬁrst study that relates a genetic
polymorphism to improvement following episodes ofpsychiatric disease. However, the above mentioned differ-
ences compared to the study of Strohmaier et al. (2013)
emphasize the need for an independent replication.
We used the GAF scale to assess the course of psychoso-
cial adaptation. This instrument is an easy-to-use method
that needs relatively little information (Dworkin et al.,
1990; Endicott et al., 1976). It correlates well with both
symptom ratings (Skodol et al., 1988) and psychosocial
variables (Startup et al., 2002). Moreover, the GAF scale
has been shown to be a sensitive instrument in multiple-
rater longitudinal studies (Dworkin et al., 1990).
Our approach mimics a longitudinal design. While we
consider this to be a particular strength of our study, the
retrospective measurement of GAF values (psychosocial
adaptation) is certainly a limitation. Although earlier stu-
dies caution against the use of retrospective assessment
when investigating psychosocial variables (Henry et al.,
1994), it should be emphasized that, in the present study,
raters maximized reliability by integrating information from
different sources (patient interview, medical records,
U. Heilbronner et al.2268relatives) and did not solely rely on the recollection of study
participants.
A further limitation of the present study is also the lack of
systematically collected information on medication. Psy-
chotropic medication is known to inﬂuence GAF ratings
(Jones et al., 1995), and medication adherence is an
important predictor of disease outcome (e.g. Ascher-
Svanum et al., 2006; Verdoux et al., 2000). However, the
lack of sex-speciﬁc differences in medication adherence
(Lacro et al., 2002) argues against confounding of the sex-
genotype interactions studied herein.
Finally, the sample size, while not large in comparison
with studies on diagnostic categories, is the largest to date
for studying genetics of longitudinal global functioning in
SZspec and BDs. Our study underscores the need for studies
investigating the complex interplay between sex and con-
ﬁrmed risk variants on longitudinal disease characteristics.
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